Genetic diversity of transmission blocking vaccine candidate (Pvs25 and Pvs28) antigen in Plasmodium vivax clinical isolates from Iran

Acta Tropica

Volumn 109, Issue 3, 2009, Pages 176-180

  Zakeri, Sedigheh ^a   Razavi, Sepand ^a   Djadid, Navid Dinparast ^a  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

Genetic diversity; Malaria vaccine; Ookinete surface protein 25 (Pvs25); Plasmodium vivax; Pvs28

Indexed keywords

MALARIA VACCINE;

ANTIGEN; GENETIC STRUCTURE; GENETIC VARIATION; MALARIA; MUTATION; PARASITE; POLYMORPHISM; PROTEIN; PROTOZOAN; VACCINE;

ARTICLE; BANGLADESH; BRAZIL; CONTROLLED STUDY; DISEASE TRANSMISSION; ENDEMIC DISEASE; GENE MUTATION; GENE SEQUENCE; GENE STRUCTURE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; INDIA; INDONESIA; IRAN; MALARIA; MEXICO; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; PLASMODIUM VIVAX; POPULATION; PROPHYLAXIS; SOUTHERN BLOTTING; THAILAND;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; ANTIGENS, PROTOZOAN; ANTIGENS, SURFACE; CLINICAL TRIALS AS TOPIC; DNA, PROTOZOAN; GENETIC VARIATION; HAPLOTYPES; HUMANS; IRAN; MALARIA VACCINES; MALARIA, VIVAX; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; PLASMODIUM VIVAX; SEQUENCE ANALYSIS, DNA; SEQUENCE HOMOLOGY;

PLASMODIUM VIVAX; TULIP BREAKING VIRUS;

EID: 59049092636     PISSN: 0001706X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.actatropica.2008.09.012     Document Type: Article

References (18)

1. Bruce M.C., and Day K.P. Cross-species regulation of malaria parasitaemia in the human host. Curr. Opin. Microbiol. 5 (2002) 431-437
2. Guerra C.A., Snow R.W., and Hay S.I. Mapping the global extent of malaria in 2005. Trends. Parasitol. 22 (2006) 353-358
3. Herrera S., Corradin G., and Arevalo-Herrera M. An update on the search for a Plasmodium vivax vaccine. Trends Parasitol. 23 3 (2006) 122-128
4. Hisaeda H., Stowers A.W., Tsuboi T., Collins W.E., Sattabongkot J., Suwanabum N., et al. Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes. Infect. Immun. 68 (2000) 6618-6623
5. Kaslow D.C. Transmission-blocking immunity against malaria and other vector-borne diseases. Curr. Opin. Immunol. 5 (1992) 557-565
6. Kaslow D.C. Transmission blocking vaccines. In: Hoffman S.L. (Ed). Malaria Vaccine Development (1996), ASM Press, Washington, DC 181-228
7. Kumar N., and Carter R. Biosynthesis of two stage-specific membrane proteins during transformation of Plasmodium gallinaceum zygotes into ookinetes. Mol. Biochem. Parasitol. 14 (1985) 127-139
8. Malkin E.M., Durbin A.P., Diemert D.J., Sattabongkot J., Wu Y., Miura K., Long C.A., Lambert L., Miles A.P., Wang J., Stowers A., Miller L.H., and Saul A. Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 23 (2005) 3131-3138
9. Mendis K., Sina B.J., Marchesini P., and Carter R. The neglected burden of Plasmodium vivax malaria. Am. J. Trop. Med. Hyg. 64 1-2 Suppl (2001) 97-106
10. Sattabongkot J., Tsuboi T., Hisaeda H., Tachibana M., Suwanabun N., Rungruang T., Cao Y.M., Stowers A.W., Sirichaisinthop J., Coleman R.E., and Torii M. Blocking of transmission to mosquitoes by antibody to Plasmodium vivax malaria vaccine candidates Pvs25 and Pvs28 despite antigenic polymorphism in field isolates. Am. J. Trop. Med. Hyg. 69 5 (2003) 536-541
11. Saul A., Hensmann M., Sattabongkot J., Collins W.E., Barnwell J.W., Langermans J.A., Wu Y., Long C.A., Dubovsky F., and Thomas A.W. Immununogenicity in rhesus of the Plasmodium vivax mosquito stage antigen Pvs25H with Alhydrogel and Montanide ISA 720. Parasite. Immunol. 29 10 (2007) 525-533
12. Snounou G., Viriyakosol S., Zhu X.P., Jarra W., Pinheiro L., do Rosario V.E., Thaithong S., and Brown K.N. High sensitivity of detection of human malaria parasites by the use of nested polymerase chain reaction. Mol. Biochem. Parasitol. 61 (1993) 315-320
13. Stowers A., and Carter R. Current developments in malaria transmission-blocking vaccines. Exp. Opin. Biol. Ther. 1 (2001) 619-628
14. Tsuboi T., Kaneko O., Cao Y.M., Tachibana M., Yakushijin Y., Nagao T., Kanbara H., and Torii M. A rapid genotyping method for the vivax malaria transmission blocking vaccine candidates, Pvs25 and Pvs28. Parasitol. Int. 53 (2004) 211-216
15. Tsuboi T., Tachibana M., Kaneko O., and Torii M. Transmission-blocking vaccine of vivax malaria. Parasitol. Int. 52 (2003) 1-11
16. Tsuboi T., Kaslow D.C., Gozar M.M., Tachibana M., Cao Y.M., and Torii M. Sequence polymorphism in two novel Plasmodium vivax ookinete surface proteins, Pvs25 and Pvs28 that are malaria transmission-blocking vaccine candidates. Mol. Med. 4 (1998) 772-782
17. Wu W., Ellis R.D., Shaffer D., Fontes E., Malkin E.M., Mahanty S., Fay M.P., Narum D., Rausch K., Miles A.P., Aebig J., Orcutt A., Muratova O., Song G., Lambert L., Zhu D., Miura K., Long C., Saul A., Miller L.H., and Durbin A.P. Phase 1 trail of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with Montanide ISA 51. PLoS One. 3 7 (2008) e2636
18. Zakeri S., Mehrizi A.A., Mamaghani S., Noorizadeh S., Snounou G., and Djadid N.D. Population structure analysis of Plasmodium vivax in areas of Iran with different malaria endemicity. Am. J. Trop. Med. Hyg. 74 (2006) 394-400